(GlobeNewswire) - Sprint Bioscience AB (publ) (Sprint Bioscience) and Bayer HealthCare (Bayer)
have entered into a collaboration and license agreement for the research,
development, and commercialization of oncological drug candidates. Under the
agreement, Sprint Bioscience licenses an early-stage inhibitor program targeting
tumor metabolism to Bayer. Subsequently, Bayer will have full control over
further development and worldwide commercialization rights for potential cancer
therapeutics and diagnostics.
– “We are very happy to have entered into this agreement for one of our tumor
metabolism projects. We are convinced that Bayer is a perfect partner to further
develop this program. This agreement also gives us the opportunity to further
invest in the expansion of our portfolio within the area of tumor metabolism,”
said Dr Anders Åberg, CEO of Sprint Bioscience.
“Bayer is committed to translating the findings of cancer research into
effective therapies to improve the quality of life of patients. Addressing the
metabolism of cancer cells is a promising approach in oncology and one of our
focus areas in cancer research at Bayer,” said Professor Andreas Busch, Head of
Global Drug Discovery and member of the Executive Committee of Bayer HealthCare.
“We are looking forward to expanding our portfolio in this area through the
agreement with Sprint Bioscience. This early research program has the potential
to lead to new treatment options for cancer patients.”
As a result of a tumor's uncontrolled growth, cancer cells exhibit an altered
metabolism (tumor metabolism) and thereby are often resistant to conventional
radiation- and chemotherapy. Sprint Bioscience has developed molecules
inhibiting a novel metabolic target, which is vital for cancer cell survival.
Such inhibitors can potentially lead to effective new treatments by selectively
affecting cancer cells.
Sprint Bioscience is eligible to receive up to approximately 190 Million Euro in
potential preclinical, clinical and net sales based milestone payments,
including an upfront payment from Bayer upon signing of the agreement.
Furthermore, Sprint Bioscience is also eligible to receive royalties on
worldwide net sales of any resulting products under the collaboration.
About Sprint Bioscience
Sprint Bioscience AB (publ) is part of the new Swedish pharmaceutical industry.
The company has the goal to develop drug candidates for the global
pharmaceutical market within the field of oncology in a more time- and resource
-efficient manner. Sprint Bioscience is situated in Stockholm, Sweden. Sprint
Bioscience share is listed on NASDAQ First North and traded under the name
Additional information is available on the company website;
Certified Advisor is Redeye, www.redeye.se.
About Bayer HealthCare
The Bayer Group is a global enterprise with core competencies in the fields of
health care, agriculture and high-tech materials. Bayer HealthCare, a subgroup
of Bayer AG with annual sales of around EUR 20.0 billion (2014), is one of the
world’s leading, innovative companies in the healthcare and medical products
industry and is based in Leverkusen, Germany. The company combines the global
activities of the Animal Health, Consumer Care, Medical Care and Pharmaceuticals
divisions. Bayer HealthCare’s aim is to discover, develop, manufacture and
market products that will improve human and animal health worldwide. Bayer
HealthCare has a global workforce of 60,700 employees (Dec 31, 2014) and is
represented in more than 100 countries. More information is available at
For further information, please contact:
Anders Åberg, CEO, Sprint Bioscience
Tel: +46-8-411 44 55
Sprint Bioscience AB (publ) is required to publish this information pursuant to
the Securities Markets Act and/or the Act on trading in financial instruments.
The information was submitted for publication on July 28, 2015 at 8:30 (CEST).
Sprint Bioscience ? Teknikringen 38A ?114 28 Stockholm ? Sweden ? 46-(0)8-411 44
For the original version on GlobeNewswire visit: http://globenewswire.com/news-release/2015/07/28/755423/0/en/Sprint-Bioscience-enters-into-collaboration-with-Bayer-HealthCare-on-tumor-metabolism-program.html
(c) 2015 Al Sidra Media LLC Provided by SyndiGate Media Inc. (Syndigate.info)., source Middle East & North African Newspapers